Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331.
Sci Rep. 2015.
PMID: 26573509
Free PMC article.
Clinical Trial.